A Multicenter Retrospective Study to understand the clinical characteristics, treatment pathway and resource utilization for patients with chronic lymphocytic leukemia A retrospective, multi-centre, observational study to describe disease characteristics, treatment patterns, treatment-related outcomes, and resource utilization for Chronic Lymphocytic Leukemia (CLL) patients in multiple international regions
CREEK is a retrospective, observational, registry-based study including patients with an incidental diagnosis of CLL and started treatment (1st line, 2nd line, or Subsequent lines of treatment) within the period between 01 June 2016 and 12 months before data collection as identified from the patient records (from participating hospitals across the GCC States and the International region countries) with at least 12 months of follow-up, after starting on treatment. Moreover, the study will include a pilot cohort in the GCC as an exploratory objective to describe the clinical and patient characteristics for the treatment-naive CLL patient
Study Type
OBSERVATIONAL
Enrollment
1,088
To describe the clinical characteristics for with chronic lymphocytic leukemia (CLL) patients
To describe the clinical characteristics for with chronic lymphocytic leukemia (CLL) patients, recording the patient characteristic: \- Demographics: (Age, gender, race, nationality, Performance status, Tobacco use, Family history of malignancies)
Time frame: 5 year
Calculation of Epidemiological Measure(s) of Interest
Calculation of Epidemiological Measure(s) of Interest e.g., descriptive statistics, hazard ratios, incidence rates, test/retest reliability)
Time frame: 5 years
To describe the clinical characteristics for with chronic lymphocytic leukemia (CLL) patients
To describe the clinical characteristics for with chronic lymphocytic leukemia (CLL) patients, recording the patient characteristic: * Laboratory Status: * CBC: Hemoglobin, Total leucocytic count, neutrophils, lymphocytes, and platelets * Renal functions: serum creatinine, Urea, eGFR * Hepatic function: ALT and AST * Concomitant medications: * Antagonists of vitamin K * Oral Anticoagulants: rivaroxaban, apixaban, dabigatran * Proton pump inhibitors (PPIs) * H2 Antagonists * Antacids * Others
Time frame: 5 Years
To describe the clinical characteristics for with chronic lymphocytic leukemia (CLL) patients
To describe the clinical characteristics for with chronic lymphocytic leukemia (CLL) patients, recording the patient characteristic: * Comorbidities. * Risk stratification
Time frame: 5 Years
To describe disease Characteristics
To describe Staging of disease, Prognosis, Cytogenetics abnormalities and Immunogenetic analysis * Date of diagnosis * Staging of disease
Time frame: 5 Years
To describe disease Characteristics
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Buenos Aires, Argentina
Research Site
Buenos Aires, Argentina
Research Site
Campinas, Brazil
Research Site
Jaú, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
Providencia, Chile
Research Site
Bogotá, Colombia
Research Site
Cali, Colombia
...and 42 more locations
To describe Staging of disease, Prognosis, Cytogenetics abnormalities and Immunogenetic analysis * Prognosis made by fluorescence in situ hybridization (FISH) * Immunogenetic analysis
Time frame: 5 Years
Recording the treatment patterns
Percentage of patients who received immediate therapy and median time of observation, Number of prior lines of treatment received.
Time frame: 5 years
Calculation of Epidemiological Measure(s) of Interest
* First Treatment received: * Number of prior lines of treatment received
Time frame: 5 Years
Subsequent lines of therapies
Type of regimen (CIT or targeted therapies) and specific regimens or drugs * Number of cycles * Duration of treatment * Pattern of response at the end of the treatment
Time frame: 5 Years